Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 30,616 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 30,616 shares of the business’s stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $0.57, for a total transaction of $17,451.12. Following the completion of the transaction, the director directly owned 2,236,055 shares in the company, valued at $1,274,551.35. This trade represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Luke Evnin also recently made the following trade(s):

• On Thursday, January 15th, Luke Evnin sold 37,413 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.55, for a total transaction of $20,577.15.
• On Tuesday, January 13th, Luke Evnin sold 43,198 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.55, for a total transaction of $23,758.90.
• On Monday, January 12th, Luke Evnin sold 58,980 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.57, for a total value of $33,618.60.
• On Friday, January 9th, Luke Evnin sold 24,678 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $15,053.58.
• On Thursday, January 8th, Luke Evnin sold 7,716 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $4,861.08.
• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $7,625.60.
• On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.62, for a total transaction of $15,476.44.

Werewolf Therapeutics Stock Performance

HOWL traded down $0.03 on Thursday, hitting $0.55. The company’s stock had a trading volume of 663,533 shares, compared to its average volume of 489,381. Werewolf Therapeutics, Inc. has a 12 month low of $0.53 and a 12 month high of $2.38. The firm has a market cap of $26.74 million, a P/E ratio of -0.34 and a beta of 0.77. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The company’s 50 day simple moving average is $0.85 and its 200-day simple moving average is $1.24.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on HOWL shares. Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Citigroup cut shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Wedbush lowered shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target for the company. in a research report on Friday, December 19th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics during the second quarter worth about $92,000. Vanguard Group Inc. raised its holdings in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after buying an additional 109,796 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Werewolf Therapeutics by 1.2% during the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares in the last quarter. Jane Street Group LLC bought a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $409,000. Finally, Citadel Advisors LLC purchased a new stake in Werewolf Therapeutics in the third quarter worth approximately $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.